Lysosomal Storage Diseases Therapeutics Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Lysosomal Storage Diseases Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, others), By Indication (Gaucher's Disease, Fabry Disease, Pompe's Disease, Mucopolysaccharidosis, others), By End User (Hospitals, Clinics), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Lysosomal Storage Diseases Therapeutics Market is projected to expand from USD 7.69 Billion in 2025 to USD 11.72 Billion by 2031, demonstrating a compound annual growth rate (CAGR) of 7.28%. These therapeutics involve specific medical interventions, such as enzyme replacement and substrate reduction therapies, designed to counteract the metabolic deficiencies stemming from lysosomal dysfunction. This market's expansion is primarily fueled by advancements in diagnostic capabilities, including newborn screening, and substantial public-private investments in research for orphan drugs. For instance, the National Institutes of Health allocated approximately $26 million in grants to the Rare Diseases Clinical Research Network in fiscal year 2025, underscoring the significant financial commitment to advance clinical studies for these conditions.
Despite this progress, a considerable hurdle impeding market growth is the exceptionally high cost associated with drug development and the subsequent pressure on pricing. Furthermore, the intricate regulatory environment, coupled with the difficulty of enrolling a sufficient number of participants for clinical trials due to small and geographically dispersed patient populations, creates significant obstacles that can delay the commercial introduction of new therapeutics.
Market Driver
Advancements in enzyme replacement and gene therapies are fundamentally transforming the Global Lysosomal Storage Diseases Therapeutics Market by shifting the clinical focus from mere palliative care to targeted disease modification. Innovative biologics are now engineered with improved cellular uptake mechanisms to more effectively address the underlying metabolic deficiencies of these complex conditions, thereby driving substantial commercial adoption. The commercial impact of these next-generation treatments is clearly reflected in the rapid growth of specialized portfolios; for example, Chiesi Group's Rare Diseases business unit achieved a 31.4% growth rate in the first half of 2025, highlighting the strong demand for its advanced therapeutic solutions.
Concurrently, supportive orphan drug policies and regulatory incentives play a crucial role in sustaining the high-risk development pipelines essential for these niche indications. Government programs offering market exclusivity and accelerated review pathways provide the necessary economic safeguards for biopharmaceutical companies to invest in treatments for limited patient populations. The effectiveness of this supportive framework is evident in regulatory outcomes, with 52% of novel drugs approved by the FDA in 2024 designated for rare diseases. This policy-driven environment directly translates into commercial sustainability, as demonstrated by Amicus Therapeutics reporting third-quarter 2025 total revenue of $169.1 million, confirming the ongoing financial viability of precision medicines in this sector.
Market Challenge
The prohibitive expense of drug development, alongside the inherent difficulties in recruiting an adequate number of participants for clinical trials, acts as a significant constraint on the Global Lysosomal Storage Diseases Therapeutics Market. These financial and logistical barriers escalate the attrition rate of new therapies, as companies face extended timelines and mounting costs to establish safety and efficacy in small, geographically dispersed patient groups. This high-risk environment often discourages sustained investment in all but the most commercially promising candidates, effectively narrowing the pipeline of potential treatments and decelerating the overall pace of market expansion.
The consequences of these hurdles are evident in the substantial gap between identified metabolic deficiencies and available medical interventions. According to the National Organization for Rare Disorders, over 95% of rare diseases still lacked an FDA-approved treatment in 2025. This statistic underscores the severity of the challenge: even with improved diagnostic capabilities, the economic burden of development often prevents the successful commercialization of therapies for the vast majority of these conditions, thereby limiting revenue growth and market maturity within the sector.
Market Trends
A distinct shift toward oral substrate reduction therapies is transforming the treatment landscape by offering a non-invasive alternative to lifelong intravenous infusions. This trend addresses the patient burden by inhibiting the accumulation of toxic substrates through convenient oral dosing, rather than relying exclusively on systemic enzyme replacement. The commercial appeal of this modality is robust; for example, Sanofi reported sales for its oral therapy Cerdelga reached 81 million Euros in Q3 2024, highlighting the sustained market demand for patient-centric delivery mechanisms, particularly in the Gaucher disease segment.
The strategic consolidation of orphan drug pipelines has emerged as a crucial mechanism for ensuring financial sustainability within the high-risk rare disease sector. Biopharmaceutical companies are increasingly assembling diverse portfolios of commercial-stage assets and late-stage candidates to mitigate the volatility associated with dependency on a single product. This diversified approach is yielding measurable stability, as demonstrated by Ultragenyx, which achieved total revenue of 139 million Dollars in Q3 2024, validating the economic strength of a consolidated platform focused on multiple rare metabolic indications.
Key Market Players
* Pfizer, Inc.
* Sanofi SA
* BioMarin Pharmaceutical Inc
* Actelion Ltd.
* Raptor Pharmaceutical Corp.
* Protalix Biotherapeutics Inc.
* Amicus Therapeutics, Inc.
* Quest Diagnostics Inc.
* Amicus Therapeutics Inc.
* Shire Plc
Report Scope
In this report, the Global Lysosomal Storage Diseases Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Lysosomal Storage Diseases Therapeutics Market, By Treatment
* Enzyme Replacement Therapy
* Stem Cell Therapy
* Substrate Reduction Therapy
* others
# Lysosomal Storage Diseases Therapeutics Market, By Indication
* Gaucher's Disease
* Fabry Disease
* Pompe's Disease
* Mucopolysaccharidosis
* others
# Lysosomal Storage Diseases Therapeutics Market, By End User
* Hospitals
* Clinics
# Lysosomal Storage Diseases Therapeutics Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Lysosomal Storage Diseases Therapeutics Market.
Available Customizations:
Global Lysosomal Storage Diseases Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Lysosomal Storage Diseases Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, others)
5.2.2. By Indication (Gaucher's Disease, Fabry Disease, Pompe's Disease, Mucopolysaccharidosis, others)
5.2.3. By End User (Hospitals, Clinics)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Lysosomal Storage Diseases Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment
6.2.2. By Indication
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Lysosomal Storage Diseases Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment
6.3.1.2.2. By Indication
6.3.1.2.3. By End User
6.3.2. Canada Lysosomal Storage Diseases Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment
6.3.2.2.2. By Indication
6.3.2.2.3. By End User
6.3.3. Mexico Lysosomal Storage Diseases Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment
6.3.3.2.2. By Indication
6.3.3.2.3. By End User
7. Europe Lysosomal Storage Diseases Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment
7.2.2. By Indication
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Lysosomal Storage Diseases Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment
7.3.1.2.2. By Indication
7.3.1.2.3. By End User
7.3.2. France Lysosomal Storage Diseases Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment
7.3.2.2.2. By Indication
7.3.2.2.3. By End User
7.3.3. United Kingdom Lysosomal Storage Diseases Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment
7.3.3.2.2. By Indication
7.3.3.2.3. By End User
7.3.4. Italy Lysosomal Storage Diseases Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment
7.3.4.2.2. By Indication
7.3.4.2.3. By End User
7.3.5. Spain Lysosomal Storage Diseases Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment
7.3.5.2.2. By Indication
7.3.5.2.3. By End User
8. Asia Pacific Lysosomal Storage Diseases Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment
8.2.2. By Indication
8.2.3. By End User
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Lysosomal Storage Diseases Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment
8.3.1.2.2. By Indication
8.3.1.2.3. By End User
8.3.2. India Lysosomal Storage Diseases Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment
8.3.2.2.2. By Indication
8.3.2.2.3. By End User
8.3.3. Japan Lysosomal Storage Diseases Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment
8.3.3.2.2. By Indication
8.3.3.2.3. By End User
8.3.4. South Korea Lysosomal Storage Diseases Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment
8.3.4.2.2. By Indication
8.3.4.2.3. By End User
8.3.5. Australia Lysosomal Storage Diseases Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment
8.3.5.2.2. By Indication
8.3.5.2.3. By End User
9. Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment
9.2.2. By Indication
9.2.3. By End User
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Lysosomal Storage Diseases Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment
9.3.1.2.2. By Indication
9.3.1.2.3. By End User
9.3.2. UAE Lysosomal Storage Diseases Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment
9.3.2.2.2. By Indication
9.3.2.2.3. By End User
9.3.3. South Africa Lysosomal Storage Diseases Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment
9.3.3.2.2. By Indication
9.3.3.2.3. By End User
10. South America Lysosomal Storage Diseases Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment
10.2.2. By Indication
10.2.3. By End User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Lysosomal Storage Diseases Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment
10.3.1.2.2. By Indication
10.3.1.2.3. By End User
10.3.2. Colombia Lysosomal Storage Diseases Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment
10.3.2.2.2. By Indication
10.3.2.2.3. By End User
10.3.3. Argentina Lysosomal Storage Diseases Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment
10.3.3.2.2. By Indication
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Lysosomal Storage Diseases Therapeutics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Pfizer, Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Sanofi SA
15.3. BioMarin Pharmaceutical Inc
15.4. Actelion Ltd.
15.5. Raptor Pharmaceutical Corp.
15.6. Protalix Biotherapeutics Inc.
15.7. Amicus Therapeutics, Inc.
15.8. Quest Diagnostics Inc.
15.9. Amicus Therapeutics Inc.
15.10. Shire Plc
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們